<PAGE>
<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 11 )*
THE COOPER COMPANIES, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.10 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
216648402
------------------------------------
(CUSIP Number)
Harold L. Schneider, Esq.
Tenzer Greenblatt LLP
405 Lexington Avenue, New York, New York 10174 (212) 573-4348
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notice and
Communications)
February 19, 1997
----------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [ ]. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
<PAGE>
SCHEDULE 13D
CUSIP NO. 216648402 PAGE 2 OF 4 PAGES
---------- --- ---
<TABLE>
<C> <S> <C>
- ---------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Cooper Life Sciences, Inc.
94-2563513
- ---------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
- ---------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
Not Applicable
- ---------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- ---------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- ---------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
1,567,533 shares of Common Stock
NUMBER OF
SHARES -------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY -0-
EACH
REPORTING -------------------------------------------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 1,567,533 shares of Common Stock
-------------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- ---------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,567,533 shares of Common Stock
- ---------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
- ---------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13.42%
- ---------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- ---------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
<PAGE>
This Amendment No. 11 amends and supplements Item 5 of the Schedule 13D
filed with the Securities and Exchange Commission on June 22, 1992, as amended
by Amendment No. 1 dated November 12, 1992, Amendment No. 2 dated July 6, 1993,
Amendment No. 3 dated August 24, 1993, Amendment No. 4 dated July 14, 1994,
Amendment No. 5 dated August 15, 1994, Amendment No. 6 dated September 6, 1994,
Amendment No. 7 dated March 7, 1995, Amendment No. 8 dated August 27, 1996,
Amendment No. 9 dated December 12, 1996 and Amendment No. 10 dated February 10,
1997 (as amended, the "Schedule 13D"), by Cooper Life Sciences, Inc., a Delaware
corporation ("CLS"), relating to the Common Stock, par value $.10 per share (the
"Common Stock") of The Cooper Companies, Inc., a Delaware corporation (the
"Company"). Except as modified hereby, there has been no change in the
information previously reported in the Schedule 13D.
Item 5. Interest in Securities of Issuer.
The number of shares of Common Stock which may be deemed to be
beneficially owned by CLS has decreased by more than 1% of the
number of shares of the class which are deemed to be outstanding.
Said decrease is the result of open market sales of an aggregate
of 165,000 shares of Common Stock, as more fully set forth on
Schedule I hereto.
Page 3 of 4 Pages
<PAGE>
<PAGE>
SIGNATURE
After reasonable inquiry, and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
COOPER LIFE SCIENCES, INC.
By: /s/ Steven Rosenberg
February 21, 1997 _______________________________
_________________ Name: Steven Rosenberg
Date Title: Vice President
Page 4 of 4 Pages
<PAGE>
<PAGE>
SCHEDULE I
TO AMENDMENT NO. 11 TO SCHEDULE 13D
<TABLE>
<CAPTION>
No. of Price
Nature of Shares Per
Transaction Date Sold Share*
- ----------- ---- ------- ------
<S> <C> <C> <C>
Sale 02/05/97 8,000 $20.375
Sale 02/06/97 5,000 20.00
Sale 02/06/97 5,000 20.125
Sale 02/06/97 5,000 20.25
Sale 02/06/97 7,000 20.375
Sale 02/06/97 15,000 20.50
Sale 02/06/97 15,000 20.625
Sale 02/06/97 4,500 20.75
Sale 02/07/97 10,500 20.75
Sale 02/07/97 15,000 20.875
Sale 02/07/97 2,100 21.00
Sale 02/10/97 12,900 21.00
Sale 02/10/97 15,000 21.125
Sale 02/19/97 15,000 21.25
Sale 02/19/97 15,000 21.375
Sale 02/19/97 15,000 21.50
TOTAL 165,000
</TABLE>
- ----------
* Before payment of commissions.
